Viatris to buy Pacira for $36.50 a share
Alpha Vantage · TradingView · · AI-summarised by FinFlash
Pacira BioSciences (PCRX) has agreed to an all-cash tender offer from Viatris for $36.50 per share. The acquisition is contingent on a majority of shares being tendered and HSR clearance, after which Pacira will become a wholly-owned subsidiary of Viatris. This merger aims to provide immediate cash value to shareholders and integrate Pacira into a larger platform.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.